Search
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamidePhenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]
Mixtures: All-In-One UTI Emergency Kit, All-In-One UTI Emergency KitBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalprogression on at least one line of endocrine therapy. … [A256828] In clinical trials, imlunestrant has been investigated as monotherapy and in combination with other drugs in breast cancer patients.[A256828]
Lindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnIn Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment.
Categories: Compounds used in a research, industrial, or household settingBelinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalThe safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamideSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalIn addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. … These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).
Linagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050 … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].
Categories: Drugs Used in Diabetes, DPP-IV Inhibitors